The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital)
Nanjing, Jiangsu, 210036, China
Location status: Recruiting
Location contact
Miao Haoqi, Postgraduate
CONTACT
Shao Pengfei, Professor
CONTACT
NCT Number: NCT06714916
The goal of this observational study is to improve the management of people with renal tumour by multimodal artificial intelligence(AI). It will also measure the accuracy of the predictions from AI models. The main questions it aims to answer are:
1. whether the AI module can accurately provide tumor-related information such as Benign or malignant, subtypes, grading, stage, etc. by learning from preoperative CT images. 2. whether the AI module can help clinicians find out the most suitable surgical programme for people with renal tumor. 3. whether the AI module can integrate CT images and pathology slides, offering supplementary prognostic information to improve postoperative survival.
Participants who complete a CT(usually Contrast-enhanced CT, CECT) examination and undergo radical or partial nephrectomy will carry out active surveillance and record postoperative survival data for 5 years.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Nanjing, Jiangsu, 210036, China
Location status: Recruiting
Miao Haoqi, Postgraduate
CONTACT
Shao Pengfei, Professor
CONTACT
In this study, AI model will explore and clarify features in renal tumor CT images and pathological images that are difficult to detect manually, and then correlate them with clinical outcomes, thereby improving the diagnosis and treatment process for renal tumors. Firstly, the model can accurately distinguish renal tumor subtypes and predict stage, grade, and complexity so as to svoid misdiagnosis and assist clinicians in formulating treatment plans. Secondly, by learning from surgical videos, the model can provide additional information during surgerys, such as important anatomical landmarks, location of tumors. Finally, combining radiomics and pathomics, the model can differentiate between high-risk and low-risk patients after surgery, thus providing personalized prognostic guidance.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From enrollment to the end of 5-years' follow up
"AUC" refers to the area under the ROC (Receiver Operating Characteristic) curve, which indicates the performance of the model in predicting immunohistochemistry-related pathological information of prostate cancer after surgery, and the AUC ranges from 0-1, with the larger value indicating the better prediction effect.
Time frame: From enrollment to the end of 5-years' follow up
Kaplan-Meier Survival Analysis s a non-parametric statistic mainly used to figure out factors which indicate survival.
Contact information is provided by the study sponsor or research team.
Miao Haoqi, Postgraduate
CONTACT
Shao Pengfei, Professor
CONTACT
Shao Pengfei
Other
Mutimodal Artificial Intelligence for Optimising Renal Tumour Management: Diagnosis, Surgery and Prognosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00199888
Adenocarcinoma, Cancer of Kidney
New York, United States
View Trial DetailsNCT07304492
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07065825
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Verona, Italy
View Trial DetailsNCT03444766
Bronchial Neoplasms, Carcinoma, Bronchogenic
Bangalore, India
View Trial Details